ClinConnect ClinConnect Logo
Search / Trial NCT01990586

Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Rabeprazole Sodium Delayed Release Tablets Under Fed Conditions

Launched by TORRENT PHARMACEUTICALS LIMITED · Nov 15, 2013

Trial Information

Current as of May 08, 2025

Completed

Keywords

ClinConnect Summary

No description provided

Gender

MALE

Eligibility criteria

  • Inclusion Criteria:
  • Healthy male human volunteers within the age range of 18 to 50 years
  • A body mass index within 18-25 Kg/m2
  • Given written informed consent to participate in the study
  • Absence Of disease markers of HIV 1\& 2, hepatitis B \& C virus and RPR.
  • Absence of significant disease or clinically' significant abnormal laboratory values on laboratory evaluation, medical history and medical examination during the screening
  • A normal 12 lead ECG.
  • A normal chest X-ray (FA view)
  • Comprehension of the nature and purpose'of the study and compliance with the requirement of the entire protocol
  • No history or no evidence of hypersensitivity to rabeprazole substituted benzimidazoles or to any component of the formulation
  • No history of Anaphylaxis arid Angioedema
  • No history or presence of gastric malignancy
  • No history of significant systemic diseases
  • No history of psychiatric disorders
  • No history of addiction to any recreational drug or drug dependence
  • No donation of blood(one unit or 350 mL) within 90 days prior to study check-in
  • No participation in any clinical study within the last 90 days
  • No receipt of any prescription drugs or over-the-counter drugs (e.g.: Cold preparations, and antacid preparations' vitamins and natural products used for therapeutic benefits), within two weeks prior to study check-in
  • No history of dehydration from diarrhea, vomiting or any other reason within a period of 24.0 hours prior to study check-in
  • No family history of neurological disorders
  • Not consumed alcohol and xanthin containing food and beverages, (chocolates, tea,coffee or cola drinks) cigarettes and tobacco products for at least 48.0 hours prior to study check-in for each period.
  • Negative results for drugs of abuse (Benzodiazepines, Cocaines, Opioids, Amphetamines, Cannabinoids and Barbiturates) in urine during the day of study check-in of each period
  • Not consumed grapefruit(mosumbi/sweet lime) juice within the 48.0 hours prior to study check-in
  • Negative alcohol breath analysis during the study check-in of each period
  • Exclusion Criteria:
  • History of seizures
  • Received pharmacological agents known to significantly induce or inhibit drug metabolizing enzymes within 14 days of the start of the study
  • History of alcohol consumption for more than two units/day (1 unit=30 mL of spirit/or 1 pint of beer), or having consumed alcohol within 48.0 hours prior to check-in
  • High caffeine (more than 5 cups of coffee or tea/day) or tobacco (mote than 9 cigarettes/beedies/cigars per day) consumption
  • History of difficulty with donating blood or difficulty in accessibility of veins
  • An unusual or abnormal diet for whatever reason e.g. because of fasting due to religious reasons

About Torrent Pharmaceuticals Limited

Torrent Pharmaceuticals Limited is a leading global pharmaceutical company based in India, renowned for its commitment to developing high-quality, affordable medications across various therapeutic areas, including cardiovascular, diabetes, and oncology. With a strong focus on research and development, Torrent is dedicated to advancing healthcare through innovative drug formulations and extensive clinical trials. The company adheres to rigorous regulatory standards and collaborates with healthcare professionals to ensure the safety and efficacy of its products, ultimately striving to improve patient outcomes and enhance the quality of life worldwide.

Locations

Miyapur, Hyderabad, India

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials